Showing 3551-3560 of 5154 results for "".
- Encouraging Preclinical Results Seen for Scinai’s NanoAbs in Plaque Psoriasishttps://practicaldermatology.com/news/encouraging-preclinical-results-seen-for-scinais-nanoabs-in-plaque-psoriasis/2462006/Scinai Immunotherapeutics Ltd.’s anti‑interleukin 17 (IL‑17) NanoAbs downregulated key molecular markers that are overexpressed in plaque psoriasis, according to preclinical data relased by Scinai. Results from ex-vivo study in human psoriatic skin anticipated in Q4 2023; In-
- One to Watch: Nektar Therapeutics' Rezpegaldesleukin Shows Promise in Phase 1b AD Studyhttps://practicaldermatology.com/news/one-to-watch-nektar-therapeutics-rezpegaldesleukin-shows-promise-in-phase-1b-ad-study/2462000/Nektar Therapeutics’ rezpegaldesleukin met several clinical efficacy endpoints with statistically significance, including Body Surface Area (BSA), Dermatology Life (DLQI), and Patient-Oriented Eczema Measure (POEM) in addition to reported efficacy for Eczema Area and Severity
- New Surgical Technique Offers Hope to Folliculitis Decalvans Patientshttps://practicaldermatology.com/news/experimental-surgical-technique-offers-hope-to-folliculitis-decalvans-patients/2461997/The lack of long-term solutions in the challenging treatment of folliculitis decalvans (FD) led Sanusi Umar MD, and colleagues from Dr. U Hair and Skin Clinic to develop and patent a novel device that holds potential for sustained FD remission.
- ABMS Announces Class of 2023-2024 Visiting Scholarshttps://practicaldermatology.com/news/abms-announces-class-of-2023-2024-visiting-scholars/2461993/Gillian Heinecke, MD, an assistant clinical professor at SSM Health/Saint Louis University in St. Louis, Mo. is the American Board of Dermatology’s 2023-2024 Visiting Scholar. The American Board of Medical Specialties (ABMS) selected thirteen outstanding indivi
- The Complexion of Climate in Medical Educationhttps://practicaldermatology.com/news/the-complexion-of-climate-in-medical-education/2461992/The morning news warned us of a heatwave, but that didn’t stop 8-year-old me from putting on my usual red hoodie. The avoidance of prying eyes or hearing “is it contagious?” another time made the sweating worth it. Atopic dermatitis (AD) had claimed my skin as its home, marking
- Biosimilar News: Samsung Bioepis, Sandoz to Develop SB17, a Proposed Stelara Biosimilar to Stelarahttps://practicaldermatology.com/news/biosimilar-news-samsung-bioepis-sandoz-to-develop-sb17-a-proposed-stelara-biosimilar-to-stelara/2461991/Samsung Bioepis Co., Ltd. has entered into a commercialization agreement with Sandoz for SB17, a proposed biosimilar to Stelara (ustekinumab). Samsung Bioepis will be responsible for development, regulatory registration and manufacture and supply of the product in t
- DermTech Appoints Mark Aguillard as Chief Commercial Officerhttps://practicaldermatology.com/news/dermtech-appoints-mark-aguillard-as-chief-commercial-officer/2461990/Mark Aguillard is DermTech, Inc.’s chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech’s overall commercial strategy and execution. Prior to joining is DermTech, Mr. Aguillard served as the chief commercial officer of Epic
- ICYMI: Vaseline, CVS Partner to Bridge the Gap of Skin Care Inequities in People of Colorhttps://practicaldermatology.com/news/icymi-vaseline-cvs-partner-to-bridge-the-gap-of-skin-care-inequities-in-people-of-color/2461988/Vaseline’s recent Train the Trainer webinar helped educate CVS field leaders on the skin care inequities that exist for Black and Brown populations as part of the brand’s ongoing partnership with CVS Health. During the webcast, Boston area-based dermatologi
- Interim INTEGUMENT-OLE Results: Arcutis’ Roflumilast Cream 0.15% Performs Well in ADhttps://practicaldermatology.com/news/arcutis-roflumilast-cream-015-performs-well-in-ad/2461987/Roflumilast cream 0.15% showed durable and improved efficacy over time and a favorable safety profile in mild to moderate Atopic Dermatitis (AD), according to interim results from the INTEGUMENT-OLE long-term open-label study. Arcutis intends to submit a supplemental New Drug Applicatio
- Meet Secret DUO from Cuterahttps://practicaldermatology.com/news/meet-secret-duo-from-cetera/2461986/Cutera, Inc. is launching Secret DUO, a skin resurfacing and revitalization platform that utilizes dual non-ablative fractional technologies. Each modality can be used individually or in combination to target a wide range of aesthetic indications. Secret DUO is equipped